What's your field of interest?
Diabetes
An estimated 285 million people lived with diabetes in 2010.This number is expected to grow to 438 million by 2030. A large proportion of diabetes patients are undiagnosed, yet early diagnosis is crucial for a successful treatment outcome. The costs for patients and society are tremendous. Prevention, early diagnosis and optimal treatment are therefore essential to successful disease managementand subsequent cost control.
HUNT Biosciences will add significant value to new diabetes diagnostics and treatments in:
- The development of biomarkers for early detection of diabetes
- The development of new treatment options based on long term cohort information covering as many as three generations of family information about the progression of diabetes
- Health economy studies and subsequent documentation based on long-term follow-up of a large homogenous populatio
Hunt Biosciences key resources
-
Repository and data
– HUNT has a stable and homogenous population very low on immigration and emigration. Furthermore, the HUNT population is very well characterised through over 500 peer-reviewed publications, and more than 60 completed PhD degrees
– The HUNT Diabetes cohort consists of 6.827 HUNT donors that have been characterised in detail through several HUNT sub-studies. The scientific production includes close to 200 publications including several high impact journals (e.g. Nature, BMJ, NEJM) and 15 PhD stheses.
– Comprehensive information from questionnaires covering lifestyle parameters, such as exercise, family history and general quality of life -
Regulatory approval and quality assurance
– Speedier approval, especially if Norway is rapporteur reference/country (MRP or DCP)
– With the huge number of donors, HUNT can provide documentation for new indications on existing drugs. As part of this, HUNT also offers clinical intervention studies on very well characterised donor groups making the biobank a unique recourse in the planning of such studies
– The HUNT biobank is certified according to the ISO9001:2008 Quality Standard -
Principal Investigators and Investigations
– HUNT is part of the Medical Faculty at the Norwegian University of Science and Technology (NTNU) and the University Hospital of St. Olav. More than 1.000 medical professionals are part of the HUNT network. -
Access to other registries
– Disease cohorts and matched controls can be identified using unique personal identification numbers (PIN) and clinical end-points registries (e.g. registries forcancer, cardiovascular disease, dementia)
– Medication can be identified using the national prescription registry
– Hereditary factors related to disease can be studied linking HUNT to the national family registry
– Deceased donors can be matched using the national cause of death registry
